Related Experiment Video
Updated: May 29, 2026
Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue
Published on: December 7, 2010
Thymidylate synthase inhibitors for non-small cell lung cancer
Elena Galvani1, Godefridus J Peters, Elisa Giovannetti
1VU University Medical Center, Department of Medical Oncology, Amsterdam, The Netherlands.
Introduction:
The folate-dependent enzyme thymidylate synthase (TS) plays a pivotal role in DNA replication/repair and cancer cell proliferation, and represents a valid target for the treatment of several tumor types, including NSCLC. NSCLC is the leading cause of cancer-related mortality, and several TS inhibitors have gone into preclinical and clinical testing, with pemetrexed emerging for its approval and widespread use as first-/second-line and maintenance therapy for this disease.
Areas Covered:
This review summarizes the therapeutic options in NSCLC, as well as the background and rationale for targeting TS. The authors also review recent pharmacogenetic studies and data from clinical trials evaluating novel TS inhibitors, hoping that the reader will gain a comprehensive overview of the field of TS inhibition, specifically relating to drugs used or being developed for lung cancer patients.
Expert Opinion:
TS is a validated target in NSCLC. However, benefits from conventional chemotherapy in NSCLC have plateaued, and more cost-effective results should be obtained with individualized treatment. Accordingly, the clinical success for TS inhibitors may depend on our ability to correctly administer these agents following biomarker-driven patient selection, including TS genotype and expression, and using the right combination therapy.
Insights
Thymidylate synthase (TS) is a key target for non-small cell lung cancer (NSCLC) treatment. Personalized medicine, using biomarkers and combination therapies, is crucial for improving outcomes with TS inhibitors.
Area of Science:
- Oncology
- Pharmacogenetics
- Cancer Therapeutics
Background:
- Thymidylate synthase (TS) is essential for DNA synthesis and cancer cell growth, making it a validated therapeutic target in non-small cell lung cancer (NSCLC).
- NSCLC remains a leading cause of cancer mortality, driving the need for effective treatment strategies.
- Pemetrexed is an approved TS inhibitor widely used in NSCLC treatment.
Purpose of the Study:
- To review current therapeutic options for NSCLC.
- To provide background and rationale for targeting TS in NSCLC.
- To summarize recent pharmacogenetic studies and clinical trial data on novel TS inhibitors for lung cancer.
Main Methods:
- Literature review of therapeutic options in NSCLC.
- Analysis of the rationale for targeting TS.
- Review of pharmacogenetic studies and clinical trial data for TS inhibitors.
Main Results:
- TS is a validated target in NSCLC.
- Conventional chemotherapy benefits in NSCLC have reached a plateau.
- Novel TS inhibitors are under clinical investigation.
Conclusions:
- Individualized treatment approaches are necessary for cost-effective outcomes in NSCLC.
- Clinical success of TS inhibitors depends on biomarker-driven patient selection (e.g., TS genotype and expression).
- Optimizing combination therapies is essential for maximizing the efficacy of TS inhibitors in NSCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...